

**PHARMACY POLICY STATEMENT**  
**North Carolina Marketplace**

**results from the phase 3 clinical trials EMERGE and E**

<b>DRUG NAME</b>	<b>Aduhelm (aducanumab-avwa)</b>
BILLING CODE	J3590
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED STATUS	Home/Office/Outpatient

**Aduhelm (aducanumab) will be considered for coverage when the following criteria are met:**

**Alzheimer's Disease**

8. **Dosage allowed/Quantity limit:** After initial titration (see below), the recommended maintenance dose is 10 mg/kg every 4 weeks as an IV infusion.

If all the above requirements are met , the medication will be approved for 6 months .

For **reauthorization**:

1. Member has had a follow up assessment to determine that they have not progressed to moderate/severe dementia, as concluded by at least two of the following cognitive tests:
  - a) MMSE score of at least 19,
  - b) CDR-GS score of 1.0 or less,
  - c) CDR-SB score of 9.0 or less,
  - d) MoCA score of at least 18,
  - e) QDRS score of 12 or less; AND
2. Prior to the 7th infusion (first dose of 10 mg/kg) and 12th infusion (sixth dose of 10 mg/kg), repeat MRI must be completed to evaluate for amyloid related imaging abnormalities-edema (ARIA-E), which can be observed on MRI as brain edema, and amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H), which includes microhemorrhage. Discontinuation is warranted in those with severe symptomatic ARIA<sup>10</sup>, radiographically severe ARIA-H, and as otherwise outlined in the prescribing information.

If all the above requirements are met, the medication will be approved for an additional 6 months.

7. Sevigny J, Chiao P, Bussi re T, et al. The antibody DGXFDQXPDE UHGXFHV \$ SODTXHV LQ \$ O disease. *Nature*. 2016;537(7618):50-56. doi:10.1038/nature19323
8. Lin GA, Whittington MD, Synnott PG, McKenna A, Campbell J, Pearson SD, Rind DM. Aducanumab for Alzheimer's Disease: Effectiveness and Value; Draft Evidence Report. Institute for Clinical and Economic Review, May 5, 2021. <https://icer.org/assessment/alzheimersdisease-2021/>.
9. Ackley SF, Zimmerman SC, Brenowitz WD, et al. Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. *BMJ*. 2021;372:n156. Published 2021 Feb 25. doi:10.1136/bmj.n156
10. Cummings, J., Aisen, P., Apostolova, L.G. et al. Aducanumab: Appropriate Use Recommendations. *J Prev Alzheimers Dis* (2021). <https://doi.org/10.14283/jpad.2021.41>

Effective date: 01/01/2023

Revised date: 08/13/2021